Literature DB >> 13984786

Megaloblastosis produced by a cytosine antagonist, 1-beta-D-arabinofuranosylcytosine.

R W TALLEY, V K VAITKEVICIUS.   

Abstract

Entities:  

Keywords:  ANTIMETABOLITES; ANTINEOPLASTIC AGENTS; BONE MARROW; NUCLEOSIDES

Mesh：

Substances：

Year:  1963        PMID： 13984786

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  12 in total

Review 1.  Cytosine arabinoside in the treatment of acute myeloid leukemia: the role and place of high-dose regimens.

Authors:  W Hiddemann
Journal:  Ann Hematol       Date:  1991-04       Impact factor: 3.673

2.  Synthesis and tumour-localizing properties of [18F]-5-fluorocytosine-arabinoside and [18F]-5-fluorocyclocytidine.

Authors:  G W Visser; O Zwaagstra; G C Gorree; P Moonen; J D Herscheid; A Hoekstra
Journal:  Eur J Nucl Med       Date:  1986

Review 3.  Inching toward cure of acute myeloid leukemia: a summary of the progress made in the last 50 years.

Authors:  Peter H Wiernik
Journal:  Med Oncol       Date:  2014-07-22       Impact factor: 3.064

4.  Intra-arterial cancer chemotherapy with combined anticancer agents.

Authors:  S Fujimoto; T Miyoshi; Y Nomura; T Akao; B Ito
Journal:  Jpn J Surg       Date:  1973-03

5.  The chromosome anomalies of the megaloblastic anaemias.

Authors:  C Bottura; V Coutinho
Journal:  Blut       Date:  1968-01

6.  Severe generalized primary herpes treated with cytarabine.

Authors:  B E Juel-Jensen
Journal:  Br Med J       Date:  1970-04-18

7.  Assessment of cytosine arabinoside as an antiviral agent in humans.

Authors:  C B Lauter; E J Bailey; A M Lerner
Journal:  Antimicrob Agents Chemother       Date:  1974-11       Impact factor: 5.191

Review 8.  Cancer chemotherapy: past, present, and future--Part I.

Authors:  J C Wright
Journal:  J Natl Med Assoc       Date:  1984-08       Impact factor: 1.798

9.  AraU accumulation in patients with renal insufficiency as a potential mechanism for cytarabine neurotoxicity.

Authors:  L H Lindner; H Ostermann; W Hiddemann; A Kiani; M Würfel; T Illmer; C Karsch; U Platzbecker; G Ehninger; E Schleyer
Journal:  Int J Hematol       Date:  2008-10-04       Impact factor: 2.490

10.  Phase I clinical and pharmacokinetic study of N4-behenoyl-1-beta-D-arabinofuranosylcytosine.

Authors:  K Kimura; R Ohno; I Amaki; K Hattori; Y Hirota; A Hoshino; M Ichimaru; M Ito; I Kimura; T Maekawa
Journal:  Med Oncol Tumor Pharmacother       Date:  1986
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.